Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Expanded Program on Immunization


Background and Definition
Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in  700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.
 
EPI ِAims at:
  1. Elevating routine vaccination coverage per district to above 95%.
  2. Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
  3. Eradicating Measles and Rubella by the end of year 2018.
 
EPI Activities:
  1. Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
  2. Continuous work to keep Lebanon certified polio-free
  3. Implementation of the RED STRATEGY to reach every child, which includes:
    1. Data on the immunization coverage for children under one year of age
    2. Data on immunization coverage in Lebanon
    3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
  4. Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination 
  5. Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
  6. Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service 
  7. Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
  8. Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.
     
    ...
    144
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA01 COZAAR B Losartan potassium - 100mg 100mg Tablet 1,740,596 L.L
J01CR02 AUGMENTIN ES B Amoxicillin (trihydrate) - 600mg/5ml, Clavulanic Acid (potassium) - 42.9mg/5ml 642.9mg/5ml Powder for suspension 846,621 L.L
L02BB03 CASODEX B Bicalutamide - 150mg 150mg Tablet, film coated 10,863,782 L.L
B02BC30-V03AK TISSEEL LYO B Fibrinogen, human (clottable protein) (I) - 91mg/ml, Aprotinin, synthetic (I) - 3000KIU/ml, Thrombin, Human (II) - 500IU/ml, Calcium chloride (II) - 40μmol/ml Injectable powder for solution + solution 24,369,850 L.L
L02BB04 XTANDI B Enzalutamide - 40mg 40mg Capsule, soft 278,248,572 L.L
N03AX09 LAMICTAL B Lamotrigine - 50mg 50mg Tablet 1,753,895 L.L
P02CA03 ZENTEL B Albendazole - 400mg 400mg Tablet 169,324 L.L
A07EA06 BUDENOFALK B Budesonide - 3mg 3mg Capsule 8,554,692 L.L
B02BC30-V03AK TISSEEL LYO B Fibrinogen, human (clottable protein) (I) - 91mg/ml, Aprotinin, synthetic (I) - 3000KIU/ml, Thrombin, Human (II) - 500IU/ml, Calcium chloride (II) - 40μmol/ml Injectable powder for solution + solution 13,394,024 L.L
L01EA03 TASIGNA B Nilotinib - 200mg 200mg Capsule 412,535,139 L.L
N03AX11 TOPAMAX 25 B Topiramate - 25mg 25mg Tablet, film coated 858,715 L.L
R06AA59 CARIBAN B Pyridoxine HCl - 10mg, Doxylamine succinate - 10mg Capsule, hard, modified release 1,701,305 L.L
C09CA03 DIOVAN B Valsartan - 80mg 80mg Tablet, film coated 602,041 L.L
J01FF01 DALACIN-C B Clindamycin HCl - 150mg 150mg Capsule 287,582 L.L
L01EA03 TASIGNA B Nilotinib - 150mg 150mg Capsule 323,961,910 L.L
L02BB05 ERLEADA B Apalutamide - 60mg 60mg Tablet, film coated 264,151,186 L.L
V03AE03 FOSRENOL B Lanthanum Carbonate - 500mg 500mg Tablet, chewable 18,751,847 L.L
A10BK01 FORXIGA B Dapagliflozin - 10mg 10mg Tablet, film coated 2,927,964 L.L
J01FF01 DALACIN-C B Clindamycin HCl - 300mg 300mg Capsule 478,408 L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated 35,663,747 L.L
L02BB05 ERLEADA B Apalutamide - 60mg 60mg Tablet, film coated 264,151,186 L.L
V03AE03 FOSRENOL B Lanthanum Carbonate - 750mg 750mg Tablet, chewable 24,138,283 L.L
A07EA06 CORTIMENT MMX B Budesonide - 9mg 9mg Tablet, prolonged release 8,996,996 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated 123,564,667 L.L
L02BB06 NUBEQA B Darolutamide - 300mg Tablet, film coated 470,558,010 L.L
N03AX11 TOPAMAX B Topiramate - 50mg 50mg Tablet, film coated 1,914,976 L.L
A07EC02 ASACOL B Mesalazine - 400mg 400mg Tablet, enteric coated 5,895,437 L.L
D07CC01 FUCICORT B Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 376,276 L.L
J01CR02 AUGMENTIN B Amoxicillin (trihydrate) - 250mg, Clavulanic Acid (potassium) - 125mg 375mg Tablet, film coated 490,503 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated 154,453,246 L.L
    ...
    144
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025